Atlas Trials

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Clinical trial NCT01967823 · COMPLETED

Trial details

NCT number
NCT01967823
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
MelanomaMeningiomaBreast CancerNon-Small Cell Lung CancerHepatocellular Cancer
Start date
2013-10-24
Primary completion
2020-04-06
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.